Key result
C-reactive protein measurement lacked sufficient sensitivity to replace routine endomyocardial biopsy for monitoring acute rejection, occurring in 28% of cases with CRP ≥ 2 vs 17% with CRP ≤ 1.
Why the study?
Does C-reactive protein (CRP) measurement accurately detect acute rejection in heart transplant patients compared to endomyocardial biopsy?
Observational
Does C-reactive protein (CRP) measurement accurately detect acute rejection in heart transplant patients compared to endomyocardial biopsy?
CRP measurement lacks sufficient sensitivity to replace routine endomyocardial biopsy for monitoring acute rejection after heart transplantation, though lower CRP levels may predict responsiveness to steroid treatment.
Answers are grounded in this paper and cite their sources.
Endomyocardial biopsy remains essential for rejection surveillance after heart transplantation; Level 3 data leaves open the search for accurate noninvasive alternatives.
Histological examination of endomyocardial biopsy (EMB) is the main technique for rejection surveillance after heart transplantation. This technique is elaborate, inconvenient for the patient, and not without complications. We prospectively analyzed whether the measurement of C-reactive protein (CRP), an acute phase protein that quickly rises when there is inflammation, can serve as a marker for immunological quiescence and as an indicator for withholding EMB. During a 6-month period, CRP was measured in all patients referred for EMB as part of the routine follow-up after heart transplantation. Acute rejection in patients with a follow-up of more than 1 year was rare (1/76). In the majority of cases, EMB was taken within the 1-year post-transplantation (170/246 = 69 %). In 71/170 biopsies (42 %), CRP was ≤ 1; in the other 99/170 (58%), CRP was ≥ 2. When CRP was ≤ 1, acute rejection was diagnosed in 12/70 cases (17%). In contrast, acute rejection was found in 28/99 cases (28%) with CRP ≥ 2 (P= 0.1). Although CRP is elevated more often in the presence of acute rejection, its sensitivity does not allow CRP to replace the routine performance of EMB for monitoring rejection after heart transplantation. We did, however, find a prognostic significance with regard to the effect of rejection treatment: in all acute rejections with a CRP ≤ 3 (n= 11), steroids were effective.
No takes yet. Share an insight, caveat, or question.
Gelder et al. (1998) conducted an observational in Heart transplantation. C-reactive protein (CRP) ≥ 2 vs. CRP ≤ 1 was evaluated on Acute rejection (p=0.1). C-reactive protein measurement lacked sufficient sensitivity to replace routine endomyocardial biopsy for monitoring acute rejection, occurring in 28% of cases with CRP ≥ 2 vs 17% with CRP ≤ 1.
Synapse has enriched 10 related papers. Consider them for comparative context: